Survival grouped by PIA assay results. The Inhibited group consisted of 14 patients whose P-FLT3 levels were <15% of baseline at ≥1 point during the first cycle of therapy. The Not inhibited group consisted of 8 patients whose P-FLT3 levels were never less than 15% of baseline during the first cycle of therapy. Although there was a trend toward improved survival in the Inhibited group, this finding did not reach statistical significance.